Monday, April 1, 2013

From Bryan Liang and Tim Mackey: Stem cells, dot-com

http://www.ncbi.nlm.nih.gov/pubmed/22972840


 2012 Sep 12;4(151):151cm9. doi: 10.1126/scitranslmed.3004030.

Stem cells, dot-com.

Source

Institute of Health Law Studies, California Western School of Law, San Diego, CA 92101, USA. baliang@alum.mit.edu

Abstract

Direct-to-consumer (DTC) advertising of suspect goods and services has burgeoned because of the Internet. Despite very limited approval for use, DTC stem cell-marketed "treatments" have emerged for an array of conditions, creating global public health and safety risks. However, it remains unclear whether such use of stem cells is subject to drugs or biologics regulations. To address this gap, regulatory agencies should be given clear authority, and the international community should create a framework for appropriate stem cell use. In addition, consumer protection laws should be used to scrutinize providers.

No comments:

Post a Comment